Adaptability of clinical pharmacist led interventions in the management of anemia of chronic renal disease: optimizing care

Girish B S; Srinivasan R; Joel M. Johns; C S Meghana

doi:10.56782/pps.243

Published : 2024-09-29

Vol. 22 No. 3 (2024)

Adaptability of clinical pharmacist led interventions in the management of anemia of chronic renal disease: optimizing care

Girish B S

Srinivasan R

Joel M. Johns

C S Meghana

DOI: https://doi.org/10.56782/pps.243

Abstract

Renal anemia is a common comorbidity in chronic kidney disease (CKD) patients, typically treated with erythropoiesis-stimulating agents (ESAs) like erythropoietin. However, both over- and under-treatment are prevalent. In 2008, the Pharmacy Council of India introduced the Pharm.D course to enhance pharmaceutical care in clinical settings. While extensive studies in other countries highlight the benefits of clinical pharmacists' interventions, Indian research on this topic is limited. This prospective randomized controlled trial included CKD patients not on dialysis, with serum creatinine levels of 2-6 mg/dL and hemoglobin (Hb) levels below 12 g/dL. Participants were divided into three subgroups based on baseline Hb levels: < 10 g/dL (Group I), 10-12 g/dL (Group II), and >12 g/dL (Group III). ESAs and iron supplements were adjusted to maintain Hb levels of 10-12 g/dL. Quality of life was assessed using the Short Form Health Survey-36 questionnaire. Out of 448 participants, those in the pharmacist intervention group showed a significant shift towards Group II by the trial's end, compared to the control group. The study demonstrated a significant improvement in quality of life and physical performance, particularly for those in Group II, indicating that maintaining Hb levels at 10-12 g/dL is optimal for Indian CKD patients. This trial exemplifies the profound impact clinical pharmacists can have on patient care, highlighting their crucial role in improving healthcare outcomes through active participation and targeted interventions in clinical settings.

Keywords:

Chronic Kidney Disease, Anemia Management, Clinical Pharmacists Intervention, Pharmaceutical Care

Similar Articles

Maciej Bara, Jakub Starownik, Jakub Szydło, Patryk Gryszkiewicz, Jakub Nieznański, Dapagliflozin - new solution in chronic kidney disease treatment , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Natalia Korytowska, Beata Pytlak, Mariusz Niemczyk, CHRONIC KIDNEY DISEASE AND SELECTED ASPECTS OF KIDNEY RECIPIENTS MONITORING , Prospects in Pharmaceutical Sciences: Vol. 18 No. 4 (2020)
Jakub Olszewski, Katarzyna Kozon, Magdalena Sitnik, Katarzyna Herjan, Karolina Mikołap, Bartłomiej Gastoł, Maciej Bara, Piotr Armański, Marcin Sawczuk, Mirikizumab – a new option in the treatment of inflammatory bowel diseases , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Paulina Dąbrowska, Michał Żuber, Michał Dacka, Efficacy and safety of bempedoic acid in lipid disorder therapy: a review of clinical trials , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Michał Gackowski, Katarzyna Połomska, Natalia Szczucka, Mateusz Wylaź, Digital-based system as a tool for improving healthcare coordination - a perspective study , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Ewelina Flegiel, Magdalena Piotrowska, Magdalena Ptasznik, Aleksandra Baran, Justyna Lenart, Miłosz Podrażka, Joanna Mazurek, Hubert Stachowicz, Weronika Bartos, Monika Adamczyk, Review of the effects of sodium butyrate on obesity, inflammatory bowel disease, pregnancy and colorectal cancer , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Katarzyna Łysiak, Anna Łysiak, The role of the gut microbiome in Alzheimer's disease , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Kacper Jasiński, Paulina Oleksa, Daria Żuraw, Mateusz Sobczyk, Mikołaj Porzak, Alicja Sodolska, Bartosz Pawłowski, The effectiveness of the immune-boosting preparations in prevention and treatment of respiratory infections , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Mateusz Sobczyk, Daria Żuraw, Paulina Oleksa, Kacper Jasiński, Mikołaj Porzak, Michał Dacka, SGLT2 inhibitors and their possible use in prevention and treatment of neurological diseases , Prospects in Pharmaceutical Sciences: Vol. 22 No. 1 (2024)
Adam Piasecki, Magdalena Sitnik, Jakub Olszewski, Maciej Bara, Katarzyna Herjan, Piotr Armański, The changing landscape of mineralocorticoid receptor antagonists – finerenone in cardiovascular and renal health , Prospects in Pharmaceutical Sciences: Vol. 22 No. 1 (2024)

1 2 3 4 5 6 7 8 9 10 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF

Citation rules

B S, G., R, S., Joel M. Johns, & C S Meghana. (2024). Adaptability of clinical pharmacist led interventions in the management of anemia of chronic renal disease: optimizing care. Prospects in Pharmaceutical Sciences, 22(3), 219–224. https://doi.org/10.56782/pps.243

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

. Clement, F. M.; Klarenbach, S.; Tonelli, M.; Johnson, J. A.; Manns, B. J. The Impact of Selecting a High Hemoglobin Target Level on Health-Related Quality of Life for Patients with Chronic Kidney Disease. Arch. Intern. Med. 2009, 169 (12), 1104. DOI: 10.1001/archinternmed.2009.112 DOI: https://doi.org/10.1001/archinternmed.2009.112

Kim, S. M.; Kim, K. M.; Kwon, S. K.; Kim, H.-Y. Erythropoiesis-Stimulating Agents and Anemia in Patients with Non-Dialytic Chronic Kidney Disease. J. Korean Med. Sci. 2016, 31 (1), 55–60. DOI: 10.3346/jkms.2016.31.1.55 DOI: https://doi.org/10.3346/jkms.2016.31.1.55

Tsuruya, K.; Hayashi, T.; Yamamoto, H.; Hase, H.; Nishi, S.; Yamagata, K.; Nangaku, M.; Wada, T.; Uemura, Y.; Ohashi, Y.; Hirakata, H. Renal Prognoses by Different Target Hemoglobin Levels Achieved by Epoetin Beta Pegol Dosing to Chronic Kidney Disease Patients with Hyporesponsive Anemia to Erythropoiesis-Stimulating Agent: A Multicenter Open-Label Randomized Controlled Study. Clin. Exp. Nephrol. 2021, 25 (5), 456–466. DOI: 10.1007/s10157-020-02005-4. DOI: https://doi.org/10.1007/s10157-020-02005-4

Singh, A. K.; Szczech, L.; Tang, K. L.; Barnhart, H.; Sapp, S.; Wolfson, M.; Reddan, D. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. N. Engl. J. Med. 2006, 355 (20), 2085–2098. DOI: 10.1056/nejmoa065485 DOI: https://doi.org/10.1056/NEJMoa065485

Drüeke, T. B.; Parfrey, P. S. Summary of the KDIGO Guideline on Anemia and Comment: Reading between the (Guide)Line(S). Kidney Int. 2012, 82 (9), 952–960. DOI: 10.1038/ki.2012.270 DOI: https://doi.org/10.1038/ki.2012.270

Ene-Iordache, B.; Perico, N.; Bikbov, B.; Carminati, S.; Remuzzi, A.; Perna, A.; Islam, N.; Bravo, R. F.; Aleckovic-Halilovic, M.; Zou, H.; Zhang, L.; Gouda, Z.; Tchokhonelidze, I.; Abraham, G.; Mahdavi-Mazdeh, M.; Gallieni, M.; Codreanu, I.; Togtokh, A.; Sharma, S. K.; Koirala, P. Chronic Kidney Disease and Cardiovascular Risk in Six Regions of the World (ISN-KDDC): A Cross-Sectional Study. Lancet Glob. Health 2016, 4 (5), e307–e319. DOI: 10.1016/s2214-109x(16)00071-1 DOI: https://doi.org/10.1016/S2214-109X(16)00071-1

Varma, P. P. Prevalence of Chronic Kidney Disease in India - Where Are We Heading? Indian J. Nephrol. 2015, 25 (3), 133–133. DOI: 10.4103/0971-4065.148304 DOI: https://doi.org/10.4103/0971-4065.148304

Kovesdy, C. P. Epidemiology of Chronic Kidney Disease: An Update 2022. Kidney Int. Suppl. 2022, 12 (1), 7–11. DOI: 10.1016/j.kisu.2021.11.003 DOI: https://doi.org/10.1016/j.kisu.2021.11.003

Wilson, S.; Wahler, R.; Brown, J.; Doloresco, F.; Monte, S. V. Impact of Pharmacist Intervention on Clinical Outcomes in the Palliative Care Setting. Am. J. Hosp. Palliat. Care 2010, 28 (5), 316–320. DOI: 10.1177/1049909110391080 DOI: https://doi.org/10.1177/1049909110391080

Onatade, R.; Appiah, S.; Stephens, M.; Garelick, H. Evidence for the Outcomes and Impact of Clinical Pharmacy: Context of UK Hospital Pharmacy Practice. Eur J Hosp Pharm 2017, 25 (e1), e21–e28. DOI: 10.1136/ejhpharm-2017-001303 DOI: https://doi.org/10.1136/ejhpharm-2017-001303

Drüeke, T. B. Lessons from Clinical Trials with Erythropoiesis-Stimulating Agents (ESAs). Ren. Replace. Ther. 2018, 4 (1), Art. No: 46. DOI: 10.1186/s41100-018-0187-2 DOI: https://doi.org/10.1186/s41100-018-0187-2

Karimi, Z.; Hadi Raeisi Shahraki; Abdollah Mohammadian-Hafshejani. Investigating the Relationship between Erythropoiesis-Stimulating Agents and Mortality in Hemodialysis Patients: A Systematic Review and Meta-Analysis. PloS one 2023, 18 (11), e0293980–e0293980. DOI: 10.1371/journal.pone.0293980 DOI: https://doi.org/10.1371/journal.pone.0293980

Shah, A. A.; Donovan, K.; Seeley, C.; Dickson, E. A.; Palmer, A. J. R.; Doree, C.; Brunskill, S.; Reid, J.; Acheson, A. G.; Sugavanam, A.; Litton, E.; Stanworth, S. J. Risk of Infection Associated with Administration of Intravenous Iron: A Systematic Review and Meta-Analysis. JAMA Netw. Open 2021, 4 (11), e2133935–e2133935. DOI: 10.1001/jamanetworkopen.2021.33935 DOI: https://doi.org/10.1001/jamanetworkopen.2021.33935

National Kidney Foundation. Aging and Kidney Disease. National Kidney Foundation. https://www.kidney.org/news/monthly/wkd_aging#:~:text=Kidney%20disease%20can%20develop%20at. [Accessed on 15 May 2024]

Chronic Kidney Disease in United States, 2023. Centers for Disease Control and Prevention. https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html#:~:text=CKD%20is%20more%20common%20in,%25)%20than%20men%20(12%25. [Accessed 15 May 2024].

Lewandowski, M. J.; Krenn, S.; Kurnikowski, A.; Bretschneider, P.; Sattler, M.; Schwaiger, E.; Antlanger, M.; Gauckler, P.; Pirklbauer, M.; Brunner, M.; Horn, S.; Zitt, E.; Kirsch, B.; Windpessl, M.; Wallner, M.; Aringer, I.; Wiesholzer, M.; Hecking, M.; Hödlmoser, S. Chronic Kidney Disease Is More Prevalent among Women but More Men than Women Are under Nephrological Care. Wien. Klin. Wochenschr. 2022, 135, 89–96. DOI: 10.1007/s00508-022-02074-3 DOI: https://doi.org/10.1007/s00508-022-02074-3

Sinnakirouchenan, R.; Holley, J. L. Peritoneal Dialysis versus Hemodialysis: Risks, Benefits, and Access Issues. Adv. Chronic Kidney Dis. 2011, 18(6), 428–432. DOI: 10.1053/j.ackd.2011.09.001 DOI: https://doi.org/10.1053/j.ackd.2011.09.001

Diabetes and Chronic Kidney Disease. Centers for Disease Control and Prevention. https://www.cdc.gov/diabetes/managing/diabetes-kidney-disease.html#:~:text=How%20Diabetes%20Causes%20Kidney%20Disease,as%20well%20as%20they%20should. [Accessed 20 May 2024].

Hypertension in CKD: Core curriculum 2019. National Kidney Foundation. https://www.ajkd.org/article/S0272-6386%2819%2930094-0/fulltext#:~:text=The%20mechanisms%20of%20hypertension%20in,ESKD)%20in%20the%20United%20States. [Accessed 20 May 2024].

Ardavani, A.; Curtis, F.; Khunti, K.; Wilkinson, T. J. The Effect of Pharmacist‐Led Interventions on the Management and Outcomes in Chronic Kidney Disease (CKD): A Systematic Review and Meta‐Analysis Protocol. Health Sci. Rep. 2023, 6(1), Art. No: e1064. DOI: 10.1002/hsr2.1064 DOI: https://doi.org/10.1002/hsr2.1064

Marouf, B. H.; Ahmed Yusif, I.; Najim, R. H. Role of Pharmacist Intervention in the Management of Anemia Associated with Chronic Kidney Diseases at the Hemodialysis Setting. J. Young Pharm. 2020, 12 (2), 162–168. DOI: 10.5530/jyp.2020.12.33 DOI: https://doi.org/10.5530/jyp.2020.12.33

Girish B S

girishsharma70268@gmail.com
https://orcid.org/0000-0003-1894-7852

Affiliation:

a:1:{s:5:"en_US";s:167:"Department of Pharmacy Practice, PESU Institute of Pharmacy (Formerly PES College of Pharmacy), PES University, Electronic City, Bengaluru, Karnataka, India – 560100";} India